Stephen Dibert to retire from Canada's MEDEC
This article was originally published in Clinica
Stephen Dibert will retire as president and chief executive of MEDEC, the Canadian medical technology association, at the end of September. Mr Dibert has been at MEDEC for eight years. “Under Stephen's watch, MEDEC has doubled membership, increased its scope and reach, and successfully demonstrated the value of the medical technology industry," MEDEC chair Jim Wilson said. The MEDEC board will appoint a search committee to find the association’s next chief executive.
You may also be interested in...
The European Medicines Agency says that Shionogi’s novel antibiotic, Fetcroja, should be approved for use across Europe but that Lilly's migraine drug, Emgality, should not be authorized for the extended indication of episodic cluster headache.
EU marketing applications from Vertex and Roche have reverted to standard review timelines at the European Medicines Agency. The outcomes of three fast-track requests that companies have made for their planned filings are still unknown.
Vertex is hoping for EU approval in Q4 of its cystic fibrosis triple combination therapy, Trikafta. It wants the same licence in the EU as it has in the US, where the product has already become a best seller for the company.